|
|
Suppliers for
Basmisanil
|
Properties | CAS |
1159600-41-5 | Formula |
C21H20FN3O5S |
|
3 Registered suppliers
Molecular Formula: C21H20FN3O5S Molecular Weight: 445.4640032
Molecular Formula: C21H20FN3O5S Molecular Weight: 445.4640032
Description : Basmisanil is a highly selective inverse agonist/negative allosteric modulator GABAAα5 receptors. It was developed by Roche to treat cognitive impairment associated with Down syndrome. In Apr 2016, Roche completed the phase II in Down syndrome (In adolescents, In adults) in USA, Argentina, Canada, France, Italy, Mexico, New Zealand, Singapore, Spain and the UK. In Sep 2016, Phase-II clinical trials in Neurological disorders (In adults, In the elderly) in Spain was on going. - Molecular Weight :445.47
- Purity :98%
Molecular Formula : C21H20FN3O5S Canonical SMILES : CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4 InChI : InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3 InChIKey : VCGRFBXVSFAGGA-UHFFFAOYSA-N Solubility : Soluble in DMSO Appearance : Powder Application : Down syndrome; Neurological disorders Storage : -20°C Freezer Synonyms : (1,1-dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; RG 1662; RG-1662; RG1662; RO5186582; RO-5186582; RO 5186582
More details are to be found here
Detailed information on the suppliers of
Basmisanil
|
Properties:
... more properties and specification on Basmisanil
|
|
Privileged suppliers
Last update 2024-05-23
|